2Kanai Y, Hirohashi S. AIterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. Carcino- genesis,2007,28 ( 12 ) : 2434 -2442.
3Lomberk G. Epigeneticsf. Pancreatology ,2007,7 ( 5-6 ) :396-397.
4David P. Steensma, MD, FACP. Can hypomethylating agents pro- vide a platform for curative therapy in myelodysplastic syndromes? Best Practice & Research Clinical Haematology, 2012, (25): 443-451.
5Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann In- tern bled,2001,134(7) :573-586.
1Jackson G,Taylor P,Smith GM,et al.A multicentre,open,noncomparative phase Ⅱ study of a combination of fludarabine phosphate,cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukemia and de novo refractory anemia with excess of blasts in transformation. Br J Haematol,2001,112:127-137.
2Carney DA,Westerman DA,Tam CS,et al.Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy.Leukemia,2010,24:2056-2062.
3Lakshmikuttyamma A,Scott SA,DeCoteau JF,et al.Reexpression of epigenetically silenced AML tumorsuppressor genes by SUV39H1 inhibition.Oncogene,2010,29:576-588.
6Allen KE,Weiss CJ. Resistance may not be futile:microRNA binmarkers for chemoresistance and potential therapeutics [ J ]. Mol Cancer Ther, 2010,9(12) :3126-3136.
7Ossenkoppele G J, Graveland WJ, Sonneveld P, et al. The value of flu- darabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastie syndromes and AML in elderly patients [J]. Blood, 2004, 103(8): 2908-2913.
8Kantarjian H, Gandhi V, Cortes J, et al. A Phase 2 clinical and pharma- cologic study of clofarabine in patients with refractory or relapsed acute leukemia [ J ]. Blood,2003,102 ( 7 ) :2379-2386.
9Karp JE, Ricklis RM, Balalkrishnan K, et al. A phase 1 clinical-laborato- ry study of clofarabine followed by cyclophosphamide for adults with refactory acute leukemias a [ J ]. Blood,2007, 110 ( 6 ) : 1762-1769.
10Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs o- verall survival compared with conventional care regimens in elderly pa- tients with low bone marrow blast count acute myeloid leukemia [ J ]. J Clin Oncol,2010,28(4) :562-569.
